Figures released by this entity indicate that at the end of day 1, a total of 10 million 61 thousand 236 doses had been administered from the Soberana 02 and Soberana Plus projects, developed by the Finlay Vaccine Institute (IFV) and the first Cuban vaccine and from Latin America, Abdala, belonging to the Center for Genetic Engineering and Biotechnology (CIGB).
In this way, four million 155 thousand 261 people in the country have already received at least the first injection of any of these products during the mass vaccination processes, health intervention, intervention studies or clinical trials.